Johnson & Johnson and Google have partnered to create new robotic-assisted surgical platforms. The deal is the latest example of Google working with a major life sciences company to make a significant technological advance.
South Korea's Green Cross said it has signed an agreement with Nanolek, a Russia biopharmaceutical company, to produce its biologics in a three-month-old facility said to be state-of-the-art.
Kapstone Medical has partnered with high-profile 3-D printer Materialise to launch a service specifically for medical device entrepreneurs.
A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.
Contract drug developer Recipharm has inked a deal with Adroit Science to join forces in drug formulation.
If there is a formula for how to be creative in the biotech industry in Asia, it probably doesn't include ingredients like getting the dress code relaxed and walls of cash as far as the eye can see for basic research.
In one of its first acts as India's new leading drugmaker, Sun Pharmaceuticals announced the beginning of the end of Ranbaxy Laboratories by removing the company from the stock markets after trading has ended on April 1.
Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.
GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.